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ABSTRACT
Background    Ranitidine is a histamine 2 receptor an-
tagonist, and daijokito is a Kampo (Chinese herbal med-
icine as practiced in Japan) formula, which is tradition-
ally used for treating constipation and digestive trouble. 
Previous study demonstrated that daijokito significantly 
affected the pharmacokinetics of ranitidine in rats; how-
ever, the doses of ranitidine and daijokito in that study 
were higher than in clinical practice. Therefore, we ex-
amined the pharmacokinetic interaction between ranit-
idine and daijokito in clinical practice doses in healthy 
volunteers.
Methods    This was a randomized, open label, two-pe-
riod crossover study in healthy volunteers (n = 7). Volun-
teers received administrations of either a single dose of 
ranitidine 300 mg, or ranitidine 300 mg in combination 
with daijokito extract granules 2.5 g. Plasma concentra-
tions of ranitidine were measured over 12 h by LC/MS/
MS method.
Results    Plasma concentrations of ranitidine were 
lower with co-administration of daijokito compared 
with ranitidine alone. Co-administration of daijokito 
significantly decreased ranitidine area under the plasma 
concentration-time curve from 0 to 12 h (AUC0–12) and 
maximum plasma concentration (Cmax) with geometric 
mean (GM) ratio [90% confidence interval (CI)] for 
AUC0–12 of 0.609 (0.449, 0.826) and Cmax of 0.515 (0.345, 
0.771).
Conclusion    Co-administration of ranitidine with dai-
jokito resulted in a significant decrease in plasma level 
of ranitidine in healthy volunteers.
Key words    daijokito; drug-drug interaction; pharma-
cokinetics; ranitidine
Ranitidine is a histamine 2 receptor antagonist that is 
widely used in the treatment of peptic ulcer, gastric mu-
cosal lesion and in the control of acid secretion.1, 2 In 
addition, ranitidine is given as a proprietary drug for 
gastric pain and a heavy feeling in the stomach. It is 
also thought that the excretion amount of ranitidine un-
changed body in urine is large, and ranitidine pharmaco-
kinetic is influenced by renal function in the process of 
excretion. In cases like this, the dose of ranitidine should 
be adjusted depending on renal function.3
 Daijokito is a Kampo formula, which is traditionally 
used as a purgative for clearing internal heat in the stom-
ach and intestines and treating constipation.4, 5 It is com-
posed of magnolia bark (Magnolia officinalis), rheum 
(Rheum), bitter orange (Citrus aurantium) and sodium 
sulfate. 
 Kampo formulas play an important role in modern 
medicine and are sometimes the preferred choice in an 
effective therapeutic approach to diseases that cannot be 
identified by a single etiology. According to the ques-
tionnaire, approximately 80% of physicians use Kampo 
formulas in general practice.6 Although concomitant 
therapy using western medicine and Kampo formulas is 
often provided for the purpose of enhancing therapeu-
tic efficacy and decreasing the side effects,7, 8 there is 
insufficient information in the exact use or interaction 
of these therapies at the present time. A few studies 
have reported that Kampo formulas had some effect on 
the pharmacokinetics of drugs such as Warfarin and 
Ticlopidine hydrochloride.9, 10 Some studies focusing 
on the pharmacokinetic interaction between ranitidine 
and other medicines have been reported.11 Even though 
there were no serious adverse interactions between the 
drugs and herbal prescription medications in patients,12 
there were still life-threatening herb-drug interactions in 
rats.13
 Ranitidine is also used as an over-the-counter (OTC) 
drug and there are possibilities of its administration with 
daijokito in clinical practice. In an earlier preclinical 
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study of rats, when ranitidine and daijokito were co-ad-
ministered, ranitidine plasma concentration was lower, 
and ranitidine t1/2 was also delayed. It was demonstrated 
that daijokito signifi cantly affected the pharmacokinetics 
of ranitidine.14 However, the doses of ranitidine and dai-
jokito in this study were higher than in the human clin-
ical setting, and it remains unclear whether the clinical 
practice dose of daijokito infl uenced the pharmacokinet-
ics of ranitidine. The aim of this study was to evaluate 
the pharmacokinetic interaction between ranitidine and 
daijokito in a clinical practice dose in healthy volunteers 
in order to establish the potential clinical relevance of a 
preclinical study.
MATERIAL AND METHODS
Study population
The study was conducted in healthy male volunteers, 
20–23 years old. Physical examination, laboratory tests 
and vital signs were conducted at screening. Volunteers 
with diarrhea, abnormalities in laboratory tests or drug 
hypersensitivity were excluded from this study. All 
volunteers provided written, informed consent prior 
to study initiation and final protocol was approved by 
Ethics Review Committee of Tottori University, Fac-
ulty of Medicine in Japan (Approval No. 1955). This 
clinical study was registered with the UMIN Clinical 
Trials Registry (UMIN000013106), and was conducted 
in accordance with the ethical principles established in 
the Declaration of Helsinki and consistent with Ethical 
Guidelines for Clinical Research.
Study design and treatment
This study was a randomized, open label, two-period 
crossover design with two periods that were separated 
by at least a 5-day washout period (Fig. 1). During the 
study, volunteers received administrations of either 
ranitidine 300 mg (Treatment I), or ranitidine 300 mg in 
combination with daijokito extract granules 2.5 g (Treat-
ment II) with water during fasting. Ranitidine (Zantac 
150 mg tablet) and daijokito extract granules 2.5 g were 
purchased from GlaxoSmithKline & Co. (Tokyo, Japan) 
and Tsumura & Co. (Tokyo, Japan), respectively. For 
pharmacokinetic analyses of ranitidine, blood samples 
were collected at pre-dose and 0.5, 1, 1.5, 2, 4, 8 and 12 
h post-dose on Day 1. Venous blood (5 mL) was col-
lected into tubes and plasma samples were separated by 
centrifugation at 1,500 g and 4 °C for 10 min and stored 
frozen at –30 °C until analyzed. Urine samples also were 
collected at pre-dose (spot urine) and 0–12 h post-dose 
(pooled urine), and samples were immediately stored 
frozen at –30 °C until analyzed.
Fig.	  1	
Fig. 1. Study design. Treatment I: Ranitidine 300 mg, Treatment II: Ranitidine 300 mg in combination with daijokito extract 
granules 2.5 g.
LC/MS/MS method for ranitidine
Concentrations of ranitidine in plasma and urine were 
determined using validated liquid chromatography with 
tandem mass spectrometry (LC/MS/MS) method (AB 
SCIEX QTRAP 5500; Takara Bio, Kusatsu, Japan). For 
plasma sample preparation, 3 volume of 0 °C methanol 
were added in 1 volume of plasma sample, and vortex, 
then centrifugation at 15,000 rpm and 4 °C for 17 min. 
Upper phase samples were diluted by adding water at 
400 times. For urine sample preparation, 3 volume of 0 
°C methanol were added in 1 volume of urine sample, 
and vortex, then centrifugation at 15,000 rpm and 4 °C 
for 17 min. Upper phase samples were diluted by adding 
water at 40,000 times. The calibration curves for plasma 
and urine by absolute calibration curve method were lin-
ear over the concentration range of 0.01 to 10.00 ng/mL (r 
= 0.9998 for plasma and r = 0.9999 for urine) 
Pharmacokinetics analysis
Pharmacokinetic parameters of ranitidine were esti-
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mated by non-compartmental methods using Microsoft 
Excel. The maximum plasma concentration (Cmax) and 
time to maximum plasma concentration (Tmax) were 
directly obtained from the observed concentration-time 
data. The area under the plasma concentration-time 
curve (AUC) from zero point to last collection [area 
under the plasma concentration-time curve from 0 to 12 
h (AUC0–12)] was calculated according to the liner trap-
ezoidal rule. The terminal elimination rate constant (ke) 
was estimated by liner terminal of the terminal portion 
of the In (concentration)-time curve, and the elimination 
half-life (t1/2) was calculated as 0.693/ke accordingly.
Safety and tolerability
Safety and tolerability were evaluated by monitoring the 
adverse experiences (AEs). Clinical laboratory assess-
ment (clinical chemistry, hematology and urinalysis), 
vital signs and physical examination were performed at 
screening, pre-dose of first administration and end of 
study. 
Statistical analysis
Summary statistics including geometric mean (GM), 
percent coefficient of variance (%CV), median, mini-
mum and maximum were provided for ranitidine phar-
macokinetic  parameter. The differences of mean of 
log-transrated Cmax, AUC0–12, t1/2 and urinary excretion 
between the ranitidine plus daijokito and ranitidine alone 
were back-transformed to estimate the GM ratios with 
the 90% confi dence interval (CI). Tmax, t1/2 and urine ex-
cretion rate were compared using paired t test. Microsoft 
Excel was used to perform all statistical analyses.
RESULTS
Demographics and baseline characteristics
A total of 13 healthy male subjects submitted to a 
screening test, and 7 subjects were enrolled in this study. 
All of them completed the study without any deviation 
to the protocol and therefore used for pharmacokinetic 
analysis set. Four and 3 subjects were enrolled in Panel 
1 and 2, respectively. Baseline characteristics of each 
Panel are shown in Table 1, and there were no differenc-
es between Panels.
Ranitidine pharmacokinetic parameters
Plasma concentrations of ranitidine were lower with 
co-administration of daijokito compared with ranitidine 
alone (Fig. 2). Co-administration of daijokito signifi-
cantly decreased ranitidine AUC0–12 and Cmax with GM 
ratio (90% CI) for AUC0–12 of 0.609 (0.449, 0.826) and 
Cmax of 0.515 (0.345, 0.771) (Table 2 and Fig. 3). GM of 
ranitidine t1/2 for co-administration of daijokito was 3.72 
Table 1. Baseline characteristics
Panel 1 (n = 4)
(Treatment I to 
Treatment II)
Panel 2 (n = 3)
(Treatment II to 
Treatment I)
Age (years)
 Average 21.8 20.7
 SD 1.1 0.5
 Minimum 20 20
 Maximum 23 21
Height (cm)
 Average 170.0 171.0
 SD 4.1 0.8
 Minimum 164.0 170.0
 Maximum 175.0 172.0
Weight (kg)
 Average 56.0 64.7
 SD 4.7 7.4
 Minimum 50.0 58.0
 Maximum 63.0 75.0
BMI
 Average 19.3 22.1
 SD 1.0 2.7
 Minimum 18.3 19.6
 Maximum 20.6 26.0
Concomitant disease
 None 4 (100%) 3 (100%)
Prior therapy
 None 4 (100%) 3 (100%)
BMI, body mass index.
h, and was comparable with ranitidine alone (3.23 h). In 
addition, median ranitidine Tmax for co-administration 
of daijokito was 2.0 h, and slightly decreased compared 
with ranitidine alone (4.0 h).
Ranitidine urinary excretion
Ranitidine is the drug of renal excretion type, so we 
evaluated ranitidine urinary excretion. GM (%CV) of 
ranitidine urine output for co-administration of dai-
jokito was 14.2 mg (21.7), and signifi cantly lower than 
ranitidine alone [29.3 mg (21.1)]. The rate of ranitidine 
excreted in urine for 12 h was signifi cantly lower with 
co-administration of daijokito than ranitidine alone (Fig. 
4).
Safety and tolerability
One subject who enrolled in Panel 1 (Treatment I to 
Treatment II) reported leucocyte increase at 12 h post-
dose of Treatment II. Intensity was judged mild by the 
investigator. There were no clinically signifi cant changes 
in other clinical laboratory assessments (clinical chem-
istry, hematology and urinalysis), vital signs or physical 
examination in either Panel.
114
Y. Endo et al.
Fig.	  2	
Fig.	  3	Fig.	  3	
Fig. 2. Plasma concentration-time profi les of ranitidine. Open cir-
cles indicate the single dose of ranitidine (n = 7), and solid circles 
indicate co-administration of ranitidine and daijokito (n = 7). Each 
value is the mean value ± SD. 
Fig. 3. Ratios of ranitidine AUC0–12 and Cmax in each subject 
(ranitidine + daijokito/ranitidine) (color circles), and GM ratio and 
90% CI (black circles).
AUC0–12, area under the plasma concentration-time curve from 0 
to 12 h; CI, confi dence interval; Cmax, maximum plasma concen-
tration; GM, geometric mean. 
Table 2. Pharmacokinetic parameters of ranitidine with and without daijokito
Pharmacokinetic parameters* Ranitidine alone (n = 7) Ranitidine + daijokito (n = 7) GM ratio (90% CI)†
AUC0–12 (ng h/mL)  6917.7 (35.5)  3773.8 (23.4) 0.609 (0.449, 0.826)
Cmax (ng/mL)  1110.5 (55.1)  572.4 (43.1) 0.515 (0.345, 0.771)
t1/2 (h)  3.23 (24.0)  3.72 (27.3)  NA
Tmax (h)  4.0 (2.0–4.0)  2.0 (1.5–4.0)  NA
*Values are GM (%CV) for AUC0–12, Cmax and t1/2; median (range) for Tmax.
†GM ratio = ranitidine + daijokito/ranitidine.
AUC0–12, area under the plasma concentration-time curve from 0 to 12 h; CI, confi dence interval; Cmax, maximum plasma concentration; 
GM, geometric mean; NA, not applicable; %CV, percent coeffi cient of variance; Tmax, time to maximum plasma concentration; t1/2, elimi-
nation half-life. 
Fig. 4. GM (± SD) of the rate of ranitidine excreted in urine for 12 h. *P < 0.05 vs. 
ranitidine alone. GM, geometric mean.
Fig.	  4	
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DISCUSSION
The GM ratios (ranitidine + daijokito/ranitidine) (90% 
CI) of AUC0–12 and Cmax were 0.609 (0.449, 0.826) 
and 0.515 (0.345, 0.771), respectively, and statistical 
signifi cance was demonstrated. In an earlier preclinical 
study of rats, ranitidine mean concentration was 16.315 
and 1.455 μg/mL corresponding to ranitidine alone and 
ranitidine with daijokito, respectively, while ranitidine 
AUC0–12 was also 28.083 and 9.826 μg/L h, respective-
ly.14 These clinical study results were consistent with the 
same previous preclinical study in rats,14 and showed the 
possibility of drug-drug interaction between ranitidine 
and daijokito in a clinical practice dose. In this study, 
plasma concentrations of ranitidine were lower with 
co-administration of daijokito compared with ranitidine 
alone, although inter-individual variability was wide. It 
has been reported that the effect of ranitidine on acid 
secretion does not show any signifi cant variability, but 
inter-individual variability in bioavailability is wide.15 It 
has been also reported that a long antisecretory activity 
of ranitidine was observed, although the short half-life of 
the drug varies between 2 and 8 h.15 Additionally, it has 
been reported that ranitidine concentrations that produce 
50% of the maximal effect are about 100 ng/mL and 
the maximal effect is reached at concentrations of about 
600 ng/mL.16 Ranitidine t1/2 was comparable between 
ranitidine alone and co-administration with daijokito, 
and ranitidine Tmax under co-administration of daijokito 
slightly decreased compared with ranitidine alone in this 
study. In contrast to those data, after the addition of dai-
jokito, ranitidine Tmax was delayed with a longer half-life 
compared with ranitidine alone in rats.14
 Ranitidine is affected by the fi rst pass effect,17 and it 
is metabolized to its N- and S-oxides almost exclusively 
(more than 93%) by flavin-containing monooxygenase 
(FMO) and to desmthylranitidine by cytochrome P450 
(CYP) 2C19, 1A2 and 2D6.18 Kampo formulas affect 
cytochrome P450 and then change the process of con-
comitant drug metabolism.19, 20 However, there is no 
report that daijokito could induce the activity of FMO, 
CYP2C19, 1A2 and 2D6 which metabolize ranitidine. 
In addition, the ranitidine elimination rate constant 
(ke) of each subject in beta phase were similar between 
ranitidine alone and ranitidine with daijokito in this 
study; therefore we think that pharmacokinetic interac-
tion might not be caused in the metabolism or excretion 
phase. 
 In this study, ranitidine AUC0–12 was lower with 
co-administration of daijokito compared with ranitidine 
alone. In addition, the rate of ranitidine excreted in urine 
for 12 h was signifi cantly lower with co-administration 
of daijokito than ranitidine alone, and this is thought to 
be due to a low ranitidine absorption rate under co-ad-
ministration of ranitidine and daijokito. Ranitidine t1/2 
was comparable between ranitidine alone and co-admin-
istration with daijokito. Therefore, it seems more likely 
that the process of absorption can be an influence to 
ranitidine pharmacokinetics under the co-administration 
of daijokito.
 Pharmacokinetic interaction in the absorption pro-
cess is caused by complex formation, change of pH in 
the stomach, gastrointestinal tract motility change, and 
transporter-mediated mechanism. Change in gastro-
intestinal tract motility is one of the main factors, and 
it depends on changes in gastric emptying rate (GER). 
In general, GER is increased, and then absorption rate 
becomes faster, while the amount of absorption is in-
creased. Kampo formulas like rikkunshito and hang-
esyashinto have the effect of accelerating the gastric 
tract,32 and the amount of concomitant drug that is 
absorbed from the intestine is changed. The absorbed 
amount of ranitidine for 12 h was decreased under 
co-administration of daijokito in this study, and daijoki-
to is used for constipation and might change the ability 
of gastrointestinal tract motility; therefore the possibility 
that GER might be changed cannot be denied.
 In the intestine, both P-glycoprotein and CYP3A4 
are expressed in epithelial cells and cooperatively 
work as a barrier to orally administered drugs. Most 
substrates of CYP3A4 and P-glycoprotein overlap and 
these two proteins together function as an absorption 
barrier against xenobiotics by their coordinate tissue 
localization and co-inducibility.21 The administration of 
P-glycoprotein or CYP3A4 substrates with their other 
substrates, such as talinolol, digoxin, midazolam change 
the absorbed amount or maximum concentration of 
substrates.22–24 These are typical examples of pharma-
cokinetic interaction in intestinal drug absorption. In 
addition, some furanocoumarins in grapefruit affect the 
activities of P-glycoprotein and/or CYP3A4, resulting in 
alteration of the pharmacokinetics of western drugs.25 
Ranitidine is a P-glycoprotein substrate, and it was found 
that oral bioavailability of ranitidine was infl uenced at 
the intestinal absorption phase.26 P-glycoprotein is a 
170–180 kDa membrane glycoprotein that mediates the 
active, outward transport of a variety of mainly lipophil-
ic compounds from cells.27 P-glycoprotein is also widely 
expressed in normal tissues, including epithelial cells in 
the gastrointestinal tract and kidney tubules and endo-
thelial cells at the blood-brain barrier.28, 29 Ranitidine 
could act as a substrate for intestinal P-glycoprotein and 
it has been suggested that the balance between absorp-
tion and secretory mechanisms is a factor in determin-
ing intestinal absorption needs as a routine consideration 
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even for compounds expected to have a predominantly 
paracellular route of absorption.30 Ranitidine and dai-
jokito were administered simultaneously, so it is thought 
that pharmacokinetic interaction via p-glycoprotein 
activation by daijokito could not be induced; however 
Yu CP et al. reported that rheum, one of component of 
daijokito, activated the function of p-glycoprotein.31 
 Co-administration of ranitidine and daijokito was 
well tolerated, and no safety issues were identified 
during the study. One subject who enrolled in Panel 
1 (Treatment I to Treatment II) reported leucocyte in-
crease at 12 h post-dose of Treatment II. The AE was 
minimal deviation of reference interval, and might be 
due to dehydration.
 In summary, although the pharmacokinetic inter-
action of ranitidine and daijokito were demonstrated in 
this study, only a single dose of ranitidine and daijokito 
was evaluated. Therefore further data is needed to ex-
trapolate more evidence in clinical practice. However, 
these data call attention to the risk of ineffectiveness of 
ranitidine in concomitant use of ranitidine and daijokito 
in clinical practice. 
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